安捷伦科技公司宣布，其PD-L1 IHC 22C3 pharmDx检测试剂在Dako Omnis平台上的应用，已获得美国食品药品监督管理局（FDA）的批准，将适应症范围扩大至食管鳞状细胞癌、三阴性乳腺癌、宫颈癌以及胃或胃食管结合部腺癌。这一批准标志着该伴随诊断工具在指导多种癌症免疫治疗方案选择方面的应用得到了进一步拓展。
安捷伦科技公司宣布，其PD-L1 IHC 22C3 pharmDx检测试剂在Dako Omnis平台上的应用，已获得美国食品药品监督管理局（FDA）的批准，将适应症范围扩大至食管鳞状细胞癌、三阴性乳腺癌、宫颈癌以及胃或胃食管结合部腺癌。这一批准标志着该伴随诊断工具在指导多种癌症免疫治疗方案选择方面的应用得到了进一步拓展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.